Carbarmazepine

PreclinicalSmall molecule

YYuanyuan Wu

Carbarmazepine is one of 11 small molecule programs targeting Trigeminal Neuralgia. It is currently in Preclinical.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

Trigeminal NeuralgiaActive, not recruiting

Trigeminal NeuralgiaPreclinical

Active, not recruiting

Competition

Competitive Landscape

13 competitors in Trigeminal Neuralgia

#DrugCompanyPhaseTrials

Tegretol

Novartis

Approved

6 2

Trileptal

Novartis

Approved

3 3

Xylocaine

MMEDRx USA, Inc.

Approved

1 4

Lamictal

GGlaxo Dba Glaxosmithkline

Approved

1 5

Intuniv

Basimglurant

1 7

Onabotulinumtoxina 100 UNT

SStanford University

Phase 3

1 8

Vimpat

UCB

Preclinical

1 9

Alloex

TThe Foundation for Orthopaedics and Regenerative Medicine

Phase 1

1 10

Cerebyx

LLupin Ltd.

Preclinical

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q4 2028

N/ANot yet recruiting

Trigeminal Neuralgia

NCT06977932

Clinical

Trials by Indication[1]

Trigeminal Neuralgia1 trial

The Alternative Effects of Electroacupuncture in the Treatment of Trigeminal Neuralgia

Not yet recruiting·YYuanyuan Wu·N/A·NCT06977932·126 enrolled

Sources

References

[1]
ClinicalTrials.gov — 1 trial record for Carbarmazepine. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — Carbarmazepine compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for Carbarmazepine. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Yuanyuan Wu company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Preclinical[1]
Company: YYuanyuan Wu

Carbarmazepine

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q4 2028

Trials by Indication[1]

Trigeminal Neuralgia1 trial

References

Drug Info

Quick Facts

Related News